BMY
Bristol-Myers Squibb Co.

20,523
Mkt Cap
$95.05B
Volume
9.01M
52W High
$63.33
52W Low
$42.52
PE Ratio
15.77
BMY Fundamentals
Price
$46.69
Prev Close
$46.63
Open
$46.72
50D MA
$45.25
Beta
0.29
Avg. Volume
17.84M
EPS (Annual)
-$4.41
P/B
5.12
Rev/Employee
$1.42M
Loading...
Loading...
News
all
press releases
AGF Management Ltd. Has $27.21 Million Stock Position in Bristol Myers Squibb Company $BMY
AGF Management Ltd. increased its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 1.4% during the second quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
AE Wealth Management LLC Purchases 185,045 Shares of Bristol Myers Squibb Company $BMY
AE Wealth Management LLC increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 271.1% in the second quarter, according to the company in its most recent filing...
MarketBeat·5h ago
News Placeholder
Harvest Portfolios Group Inc. Grows Position in Bristol Myers Squibb Company $BMY
Harvest Portfolios Group Inc. raised its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 14.9% in the second quarter, according to the company in its most recent Form 13F filing...
MarketBeat·23h ago
News Placeholder
Resona Asset Management Co. Ltd. Grows Stock Holdings in Bristol Myers Squibb Company $BMY
Resona Asset Management Co. Ltd. raised its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 6.2% in the 2nd quarter, according to the company in its most recent disclosure with...
MarketBeat·1d ago
News Placeholder
Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Saturday...
MarketBeat·1d ago
News Placeholder
Validea Detailed Fundamental Analysis - BMY
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published...
Nasdaq News: Markets·2d ago
News Placeholder
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Zacks·2d ago
News Placeholder
Bristol Myers Squibb Company $BMY Holdings Raised by Sienna Gestion
Sienna Gestion grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 9.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·2d ago
News Placeholder
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Zacks·4d ago
News Placeholder
BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025
The company has increased its adjusted revenue outlook to a range of approximately $47.5 billion to $48.0 billion, up from a previous range of roughly $46.5 billion to $47.5 billion.
Stocktwits·10d ago

Latest BMY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.